Osman Kibar

Osman Kibar is a Turkish-American entrepreneur and scientist, best known as the founder and CEO of Samumed, a biopharmaceutical company focused on tissue regeneration.

Early Life and Education[edit | edit source]

Osman Kibar was born in Izmir, Turkey. He moved to the United States for his higher education, earning a Bachelor of Science degree in Electrical Engineering from California Institute of Technology (Caltech) and a Ph.D. in Optics from the University of California, San Diego (UCSD).

Career[edit | edit source]

After completing his Ph.D., Kibar co-founded Genoptix, a specialized laboratory service provider, which was later sold to Novartis for $470 million in 2011. He then founded Samumed, a company that aims to harness the regenerative power of the Wnt signaling pathway to reverse age-related degeneration and treat diseases such as osteoarthritis, baldness, and cancer.

Recognition[edit | edit source]

Kibar has been recognized for his contributions to the field of biotechnology. In 2016, he was named in the Forbes list of global billionaires, with an estimated net worth of $4 billion. He was also listed in the PharmaVOICE 100, a list of the most inspiring people in the life sciences industry.

References[edit | edit source]

External Links[edit | edit source]

Samumed Official Website

This pharmacology-related article is a stub. You can help WikiMD by expanding it.

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.